{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:26:52Z","timestamp":1783344412558,"version":"3.54.6"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11912-019-0788-0","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T09:00:36Z","timestamp":1553677236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma"],"prefix":"10.1007","volume":"21","author":[{"given":"Pamela B.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"issue":"17","key":"788_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"\u2022 Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(17):1598\u2013607 Established the role of 3 cycles of AVD without radiation for early-stage Hodgkin lymphoma.","journal-title":"N Engl J Med"},{"issue":"27","key":"788_CR2","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","volume":"28","author":"HT Eich","year":"2010","unstructured":"Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199\u2013206.","journal-title":"J Clin Oncol"},{"issue":"23","key":"788_CR3","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","volume":"25","author":"A Engert","year":"2007","unstructured":"Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495\u2013502.","journal-title":"J Clin Oncol"},{"issue":"19","key":"788_CR4","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"788_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2010;363(7):640\u201352.","journal-title":"N Engl J Med"},{"key":"788_CR6","first-page":"CD007941","volume":"5","author":"N Skoetz","year":"2017","unstructured":"Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017;5:CD007941.","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"788_CR7","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"\u2022\u2022 Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374(25):2419\u201329 The largest trial of PET-de-escalation in advanced Hodgkin lymphoma. Established the safety of bleomycin omission following 2 cycles of ABVD in patients with an interim complete metabolic response.","journal-title":"N Engl J Med"},{"issue":"26","key":"788_CR8","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma. N Engl J Med. 2015;373(26):2499\u2013511.","journal-title":"N Engl J Med"},{"issue":"21","key":"788_CR9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.V120.21.548.548","volume":"120","author":"AE Hay","year":"2015","unstructured":"Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, et al. Treatment of stage I-II A non-bulky Hodgkin\u2019s lymphoma (HL): an individual patient-data comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 combined-modality therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. Blood. 2015;120(21):548.","journal-title":"Blood"},{"issue":"14","key":"788_CR10","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1200\/JCO.2010.32.8427","volume":"29","author":"AK Ng","year":"2011","unstructured":"Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011;29(14):1885\u201392.","journal-title":"J Clin Oncol"},{"issue":"9","key":"788_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1586\/era.10.114","volume":"10","author":"C Kobe","year":"2010","unstructured":"Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, et al. The role of PET in Hodgkin\u2019s lymphoma and its impact on radiation oncology. Expert Rev Anticancer Ther. 2010;10(9):1419\u201328.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"32","key":"788_CR12","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1200\/JCO.2007.15.5507","volume":"26","author":"KA Goodman","year":"2008","unstructured":"Goodman KA, Riedel E, Serrano V, Gulati S, Moskowitz CH, Yahalom J. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(32):5240\u20137.","journal-title":"J Clin Oncol"},{"issue":"21","key":"788_CR13","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-06-1420","volume":"12","author":"E Brusamolino","year":"2006","unstructured":"Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin\u2019s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res. 2006;12(21):6487\u201393.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"788_CR14","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","volume":"22","author":"G Bonadonna","year":"2004","unstructured":"Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. J Clin Oncol. 2004;22(14):2835\u201341.","journal-title":"J Clin Oncol"},{"issue":"4","key":"788_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","volume":"89","author":"L Specht","year":"2014","unstructured":"Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"788_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/COC.0000000000000331","volume":"39","author":"S Dhakal","year":"2016","unstructured":"Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, et al. ACR Appropriateness Criteria(R) Hodgkin lymphoma-favorable prognosis stage I and II. Am J Clin Oncol. 2016;39(6):535\u201344.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"788_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/COC.0000000000000294","volume":"39","author":"KB Roberts","year":"2016","unstructured":"Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, et al. ACR Appropriateness Criteria(R) Hodgkin lymphoma-unfavorable clinical stage I and II. Am J Clin Oncol. 2016;39(4):384\u201395.","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"788_CR18","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","volume":"24","author":"MV Maraldo","year":"2013","unstructured":"Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschold P, Petersen PM, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113\u20138.","journal-title":"Ann Oncol"},{"issue":"12","key":"788_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","volume":"32","author":"JM Raemaekers","year":"2014","unstructured":"Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2014;32(12):1188\u201394.","journal-title":"J Clin Oncol"},{"key":"788_CR20","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Andre MP, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017:Jco2016686394. One of the largest trials of PET-adapted therapy in early-stage patients. Demonstrated potential safety of omission of radiation therapy in some patients with early unfavorable disease and a complete metabolic remission.","DOI":"10.1200\/JCO.2016.68.6394"},{"issue":"15_suppl","key":"788_CR21","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/jco.2011.29.15_suppl.8034","volume":"29","author":"KJ Savage","year":"2011","unstructured":"Savage KJ, Connors JM, Klasa RJ, Hoskins P, Shenkier TN, Gascoyne RD, et al. The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. J Clin Oncol. 2011;29(15_suppl):8034.","journal-title":"J Clin Oncol"},{"issue":"23","key":"788_CR22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V126.23.579.579","volume":"126","author":"KJ Savage","year":"2015","unstructured":"Savage KJ, Connors JM, Villa DR, Hapgood G, Gerrie AS, Shenkier TN, et al. Advanced stage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation. Blood. 2015;126(23):579.","journal-title":"Blood"},{"key":"788_CR23","doi-asserted-by":"crossref","unstructured":"\u2022 Press OW, Li H, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016. One of the first trials of PET-adapted therapy in advanced-stage Hodgkin lymphoma.","DOI":"10.1200\/JCO.2015.63.1119"},{"issue":"5","key":"788_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","volume":"36","author":"A Gallamini","year":"2018","unstructured":"\u2022\u2022 Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mule A, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454\u201362 One of the largest trials of PET-adapted therapy in early-stage patients. Further established safety of escalated BEACOPP in patients failing to achieve complete metabolic remission after 2 cycles of ABVD.","journal-title":"J Clin Oncol"},{"issue":"10","key":"788_CR25","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","volume":"132","author":"DJ Straus","year":"2018","unstructured":"Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132(10):1013\u201321.","journal-title":"Blood"},{"issue":"26","key":"788_CR26","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"\u2022\u2022 Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >\/=60 years with HL. Blood. 2017;130(26):2829\u201337 The first clinical trial incorporating novel therapy and omitting anthracycline in newly diagnosed elderly Hodgkin patients. Results showed improved safety and efficacy compared to historic cohorts.","journal-title":"Blood"},{"key":"788_CR27","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018:JCO2018790139. One of the first trials incorporating novel therapy into newly diagnosed elderly Hodgkin lymphoma. Results showed improved safety and efficacy compared to historic cohorts.","DOI":"10.1200\/JCO.2018.79.0139"},{"issue":"12","key":"788_CR28","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M, von Tresckow B, B\u00f6ll B, Meissner J, et al. Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24(12):3070\u20136.","journal-title":"Ann Oncol"},{"issue":"1","key":"788_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijrobp.2016.03.052","volume":"96","author":"JR Gunther","year":"2016","unstructured":"Gunther JR, Fanale MA, Reddy JP, Akhtari M, Smith GL, Pinnix CC, et al. Treatment of early-stage unfavorable Hodgkin lymphoma: efficacy and toxicity of 4 versus 6 cycles of ABVD chemotherapy with radiation. Int J Radiat Oncol Biol Phys. 2016;96(1):110\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"788_CR30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","volume":"30","author":"B Tresckow von","year":"2012","unstructured":"von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907\u201313.","journal-title":"J Clin Oncol"},{"issue":"5","key":"788_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1111961","volume":"366","author":"RM Meyer","year":"2012","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2012;366(5):399\u2013408.","journal-title":"N Engl J Med"},{"key":"788_CR32","unstructured":"Fiaccadori V et al. Relapses in early PET-negative stage I\/II Hodgkin lymphoma after combined modality treatment or chemotherapy only in the EORTC\/LYSA\/FIL H10 trial. Abstract # 0066. International Symposium of Hodgkin Lymphoma; Cologne, Germany 2018."},{"issue":"4","key":"788_CR33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.14236","volume":"179","author":"VT Nguyen","year":"2017","unstructured":"Nguyen VT, Pophali PA, Tsai JP, Jagadeesh D, Dean RM, Pohlman B, et al. Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning. Br J Haematol. 2017;179(4):674\u20136.","journal-title":"Br J Haematol"},{"issue":"6","key":"788_CR34","first-page":"3035","volume":"37","author":"S Master","year":"2017","unstructured":"Master S, Koshy N, Wilkinson B, Rosen L, Mills G, Mansour R, et al. Effect of radiation therapy on survival in Hodgkin\u2019s lymphoma: a SEER data analysis. Anticancer Res. 2017;37(6):3035\u201343.","journal-title":"Anticancer Res"},{"issue":"13","key":"788_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","volume":"14","author":"A Younes","year":"2013","unstructured":"Younes A, Connors JM, Park SI, Fanale M, O\u2019Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348\u201356.","journal-title":"Lancet Oncol"},{"issue":"11","key":"788_CR36","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","volume":"128","author":"A Kumar","year":"2016","unstructured":"Kumar A, Casulo C, Yahalom J, Schoder H, Barr PM, Caron P, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016;128(11):1458\u201364.","journal-title":"Blood"},{"key":"788_CR37","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","volume":"34","author":"P Carde","year":"2016","unstructured":"Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score >\/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34:2028\u201336.","journal-title":"J Clin Oncol"},{"issue":"6","key":"788_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","volume":"31","author":"LI Gordon","year":"2013","unstructured":"Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31(6):684\u201391.","journal-title":"J Clin Oncol"},{"issue":"5","key":"788_CR39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805\u201311.","journal-title":"J Clin Oncol"},{"key":"788_CR40","doi-asserted-by":"crossref","unstructured":"\u2022 Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response\u2013adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016. Additional trial of PET-adapted therapy in advanced Hodgkin lymphoma.","DOI":"10.1200\/JCO.2015.63.0699"},{"issue":"1","key":"788_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/10428194.2011.602771","volume":"53","author":"LA Minuk","year":"2012","unstructured":"Minuk LA, Monkman K, Chin-Yee IH, Lazo-Langner A, Bhagirath V, Chin-Yee BH, et al. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leuk Lymphoma. 2012;53(1):57\u201363.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"788_CR42","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","volume":"19","author":"RA Anderson","year":"2018","unstructured":"Anderson RA, Remedios R, Kirkwood AA, Patrick P, Stevens L, Clifton-Hadley L, et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin\u2019s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol. 2018;19(10):1328\u201337.","journal-title":"Lancet Oncol"},{"issue":"2","key":"788_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","volume":"31","author":"K Behringer","year":"2013","unstructured":"Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231\u20139.","journal-title":"J Clin Oncol"},{"issue":"10114","key":"788_CR44","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390(10114):2790\u2013802.","journal-title":"Lancet."},{"issue":"11","key":"788_CR45","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","volume":"34","author":"F Merli","year":"2016","unstructured":"Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175\u201381.","journal-title":"J Clin Oncol"},{"issue":"11","key":"788_CR46","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","volume":"123","author":"DA Eichenauer","year":"2014","unstructured":"Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2014;123(11):1658\u201364.","journal-title":"Blood."},{"issue":"26","key":"788_CR47","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2018.78.3514","volume":"36","author":"CE Weibull","year":"2018","unstructured":"Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Bjorkholm M, Lambert PC, et al. Contemporarily treated patients with Hodgkin lymphoma have childbearing potential in line with matched comparators. J Clin Oncol. 2018;36(26):2718\u201325.","journal-title":"J Clin Oncol"},{"issue":"12","key":"788_CR48","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","volume":"34","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34(12):1376\u201385.","journal-title":"J Clin Oncol"},{"issue":"32","key":"788_CR49","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"P Borchmann","year":"2011","unstructured":"Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin\u2019s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234\u201342.","journal-title":"J Clin Oncol"},{"issue":"4","key":"788_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378(4):331\u201344.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"788_CR51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V130.Suppl_1.651.651","volume":"130","author":"R Ramchandren","year":"2017","unstructured":"Ramchandren R, Fanale MA, Rueda A, Armand P, Trn\u011bn\u00fd M, Feldman TA, et al. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 study. Blood. 2017;130(Suppl 1):651.","journal-title":"Blood."},{"key":"788_CR52","unstructured":"Ramchandren R DE, Rueda A, et al. CheckMate 205 cohort D: a phase 2 trial of nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma. Abstract #S114. 23rd Congress of the European Hematology Association; June 15, 2018; Stockholm, Sweden2018."},{"issue":"12","key":"788_CR53","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","volume":"18","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18(12):1680\u20137.","journal-title":"Lancet Oncol"},{"issue":"2","key":"788_CR54","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","volume":"119","author":"GL Stark","year":"2002","unstructured":"Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR, et al. Hodgkin\u2019s disease in the elderly: a population-based study. Br J Haematol. 2002;119(2):432\u201340.","journal-title":"Br J Haematol"},{"issue":"12","key":"788_CR55","first-page":"1369","volume":"22","author":"AM Evens","year":"2008","unstructured":"Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park). 2008;22(12):1369\u201379.","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"788_CR56","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","volume":"119","author":"AM Evens","year":"2012","unstructured":"Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692\u20135.","journal-title":"Blood."},{"key":"788_CR57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.13904","volume":"172","author":"F Zallio","year":"2016","unstructured":"Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2016;172:879\u201388.","journal-title":"Br J Haematol"},{"issue":"2 Suppl 3","key":"788_CR58","first-page":"9","volume":"31","author":"P Sonneveld","year":"1994","unstructured":"Sonneveld P, Hop W, Mulder AH, Michiels JJ, Blijham G, van de Lelie J, et al. Full-dose chemotherapy for non-Hodgkin\u2019s lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group. Semin Hematol. 1994;31(2 Suppl 3):9\u201312.","journal-title":"Semin Hematol"},{"issue":"2","key":"788_CR59","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2141.2011.08934.x","volume":"156","author":"C Nabhan","year":"2012","unstructured":"Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, et al. Analysis of very elderly (>\/=80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012;156(2):196\u2013204.","journal-title":"Br J Haematol"},{"issue":"15_suppl","key":"788_CR60","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.1200\/jco.2011.29.15_suppl.8035","volume":"29","author":"AM Evens","year":"2011","unstructured":"Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett N, Connors JM, et al. Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): analysis from the phase III randomized U.S. intergroup trial E2496. J Clin Oncol. 2011;29(15_suppl):8035.","journal-title":"J Clin Oncol"},{"issue":"24","key":"788_CR61","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","volume":"118","author":"B Boll","year":"2011","unstructured":"Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, Soekler M, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118(24):6292\u20138.","journal-title":"Blood"},{"issue":"1","key":"788_CR62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdi023","volume":"16","author":"V Ballova","year":"2005","unstructured":"Ballova V, Ruffer JU, Haverkamp H, Pfistner B, Muller-Hermelink HK, Duhmke E, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16(1):124\u201331.","journal-title":"Ann Oncol"},{"issue":"1","key":"788_CR63","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.12222","volume":"161","author":"AM Evens","year":"2013","unstructured":"Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76\u201386.","journal-title":"Br J Haematol"},{"issue":"9976","key":"788_CR64","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418\u201327.","journal-title":"Lancet"},{"issue":"2","key":"788_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bjh.13419","volume":"170","author":"A Stamatoullas","year":"2015","unstructured":"Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179\u201384.","journal-title":"Br J Haematol"},{"key":"788_CR66","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","volume":"127","author":"B Boll","year":"2016","unstructured":"Boll B, Goergen H, Behringer K, Brockelmann PJ, Hitz F, Kerkhoff A, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189\u201392.","journal-title":"Blood"},{"issue":"3","key":"788_CR67","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/10428190601126610","volume":"48","author":"A Kolstad","year":"2007","unstructured":"Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma. Leuk Lymphoma. 2007;48(3):570\u20136.","journal-title":"Leuk Lymphoma"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-019-0788-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T12:40:13Z","timestamp":1663159213000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-019-0788-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s11912-019-0788-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"27 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Pamela B. Allen declares that she has no conflict of interest.Jane N. Winter has received clinical trial funding (paid to her institution) from Merck and GlaxoSmithKline and has received compensation from Merck, Gilead, Janssen, Adicet Bio, and Bayer for participation on advisory boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"39"}}